We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF)

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: November 26, 2012
Last Update Posted: July 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Canadian Collaborative Research Network
This observational registry will characterize contemporary stroke prevention in Canadian adults with atrial fibrillation, and provide clarity in understanding physician preferences for the various oral anticoagulants available in the Canadian marketplace. This study will determine the patient profiles of those selected for the various therapies available in Canada and provide an understanding of the factors involved in drug selection and management.

Cardiovascular Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by Canadian Collaborative Research Network:

Primary Outcome Measures:
  • To determine how Canadian physicians assess stroke risk in adults with atrial fibrillation and make therapeutic decisions around anticoagulation [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • To assess the adequacy of anticoagulation in treated patients [ Time Frame: 1 year ]
  • To understand how new oral anticoagulants are incorporated into clinical practice [ Time Frame: 1 year ]
  • To assess quality of life in patients with AF [ Time Frame: 1 year ]
  • To evaluate how physicians select between rate and rhythm control options for AF [ Time Frame: 1 year ]
  • To evaluate regional differences in care [ Time Frame: 1 year ]
  • To compare management strategies between primary care physicians and cardiovascular specialists [ Time Frame: 1 year ]

Enrollment: 2499
Study Start Date: November 2013
Estimated Study Completion Date: August 15, 2017
Estimated Primary Completion Date: August 15, 2017 (Final data collection date for primary outcome measure)
  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care and specialist clinics

Inclusion Criteria:

  • Documented atrial fibrillation (ECG, rhythm strip, device interrogation, discussion of an AF diagnosis in the participant's clinical report) within the past 10 years; paroxysmal, persistent or permanent
  • Age > 18 years
  • Most recent visit for a patient having had a clinical visit with Investigator occurring within the past one year

Exclusion Criteria:

  • Valvular AF (hemodynamically significant valvular heart disease including rheumatic mitral valve disease or at least moderate aortic valve stenosis)
  • Life expectancy < 12 months
  • Active malignancy (treated or untreated)
  • Indication for systemic anticoagulation independent of atrial fibrillation (venous thromboembolism, mechanical heart valve)
  • Prior participation in any OAC randomized clinical trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01733160

Canada, Ontario
Brampton, Ontario, Canada, L6Z 4N5
Sponsors and Collaborators
Canadian Collaborative Research Network
Principal Investigator: Milan K Gupta, MD Canadian Collaborative Research Network
Principal Investigator: Andrew Ha, MD Canadian Collaborative Research Network
  More Information

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.
Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15;123(10):1144-50. doi: 10.1161/CIR.0b013e31820f14c0. Epub 2011 Feb 14.
Dorian P, Guerra PG, Kerr CR, O'Donnell SS, Crystal E, Gillis AM, Mitchell LB, Roy D, Skanes AC, Rose MS, Wyse DG. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol. 2009 Jun;2(3):218-24. doi: 10.1161/CIRCEP.108.812347. Epub 2009 Mar 31.
Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011 Jan-Feb;27(1):74-90. doi: 10.1016/j.cjca.2010.11.007.

Responsible Party: Canadian Collaborative Research Network
ClinicalTrials.gov Identifier: NCT01733160     History of Changes
Other Study ID Numbers: SPRINT-AF 18-10-2012
First Submitted: November 2, 2012
First Posted: November 26, 2012
Last Update Posted: July 21, 2017
Last Verified: July 2017

Keywords provided by Canadian Collaborative Research Network:
Atrial Fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes

To Top